Cisplatin — gemcitabine — paclitaxel (PGT) in the treatment of advanced non-small-cell lung cancer (NSCLC). A southern Italy cooperative oncology group (SICOG) phase II study
G. Frasci(Radiation Oncology Institute), G. Comella(Tumour Institute of Tuscany), N. Panza, E Micillo(Medical Center Hospital), R Cioffi(Medical Center Hospital), V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), P. Comella, G.P. Nicolella(Radiation Oncology Institute)
Cited by 3
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108